Dexcom (DXCM) FY2019 results: revenue $1.5 billion, up 43.1% on the year
Dexcom Inc. (DXCM) reported revenue of $1.5 billion for fiscal 2019, the year ended 31 December 2019, up 43.1% on the year before. Net income was $101 million, and diluted earnings per share $1.10. The figures are the company's own, from the 10-K it filed with the SEC on 13 February 2020.
Revenue
$1.5 billion
+43.1% on the year
FY2012FY2019
Operating margin
9.6%
-18.1% a year earlier
FY2012FY2019
Net income
$101 million
FY2012FY2019
Diluted EPS
$1.10
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
1,476
1,032
718
+43.1%
Cost of revenue
544
368
226
+48.1%
Gross profit
932
664
492
+40.3%
Gross margin
63.1%
64.4%
68.5%
Research and development
274
200
185
+37.0%
Selling, general and administrative
516
433
349
+19.2%
Operating income
142
-186
-42.5
Operating margin
9.6%
-18.1%
-5.9%
Interest expense
60.3
22.7
12.8
+165.6%
Pre-tax income
104
-126
-48.6
Income tax
3.1
0.6
1.6
+416.7%
Effective tax rate
3.0%
n/a
n/a
Net income
101
-127
-50.2
Net margin
6.8%
-12.3%
-7.0%
Diluted EPS
$1.10
-$1.44
-$0.58
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
314
123
92.0
+155.3%
Capital expenditure
180
67.1
66.0
+168.3%
Free cash flow
134
56.1
26.0
+139.8%
Free cash flow margin
9.1%
5.4%
3.6%
Cash from investing
-1,015
-140
-144
Cash from financing
10.7
710
399
-98.5%
Depreciation and amortisation
48.7
29.1
16.1
+67.4%
Share-based compensation
103
102
106
+0.8%
Buybacks
0.0
100
0.0
Diluted shares, weighted
92m
88m
86m
+4.6%
Shares outstanding at period end
92m
90m
87m
+1.8%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
883
663
419
+33.1%
Debt
1,060
1,010
328
+4.9%
Operating lease liabilities
72.4
0.0
n/a
Finance lease liabilities
14.4
n/a
n/a
Other liabilities
366
242
157
+50.9%
Total liabilities and equity
2,395
1,916
904
+25.0%
Fixed assets
321
183
146
+75.5%
Goodwill
18.6
18.7
12.1
-0.5%
Investments
n/a
107
122
Securities held for sale or to maturity
1,087
n/a
n/a
Cash and equivalents
446
1,137
442
-60.8%
Receivables
286
227
134
+26.3%
Inventory
120
70.7
45.2
+69.4%
Other assets
116
173
3.9
-33.0%
Total assets
2,395
1,916
904
+25.0%
10-K for the year ended 31 December 2019, filed 13 February 2020: the filing.